Key opinion leaders Aditya Bardia, MD, MPH, and Alison Conlin, MD, provide a broad view of the current metastatic triple-negative breast cancer treatment landscape.
ASCENT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Centering discussion on sacituzumab govitecan use in metastatic triple-negative breast cancer, expert oncologists reflect on results from the phase 3 ASCENT study.
Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.
Expert oncologists review the clinical data supporting the use of sacituzumab govitecan in metastatic triple-negative breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
3
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
4
In Response: Why the Passing of H.R.2541 Is Needed
5
